Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**betamethasone + loratadine** is a combination drug consisting of two active pharmaceutical ingredients: betamethasone, a synthetic glucocorticoid corticosteroid, and loratadine, a non-sedating antihistamine. The drug is primarily used as an oral solution for the short-term treatment of severe perennial allergic rhinitis and acute exacerbations of allergic rhinitis, especially in pediatric patients. Betamethasone provides potent anti-inflammatory effects by inhibiting pro-inflammatory mediators and suppressing immune responses; loratadine acts as a selective antagonist of the Histamine H1 receptor, reducing symptoms like sneezing, nasal congestion, and pruritus. Clinical studies have demonstrated superior efficacy of the combination over monotherapy for acute allergic symptoms, with good safety for short-term use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone + loratadine.